Total Payments
$474,884
2024 Payments
$79,353
Companies
27
Transactions
260
Medicare Patients
218
Medicare Billing
$32,599
Payment Breakdown by Category
Consulting$227,922 (48.0%)
Other$127,429 (26.8%)
Travel$67,722 (14.3%)
Research$28,827 (6.1%)
Education$17,519 (3.7%)
Food & Beverage$5,464 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $227,922 | 80 | 48.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,897 | 34 | 15.4% |
| Travel and Lodging | $67,722 | 41 | 14.3% |
| Honoraria | $53,459 | 8 | 11.3% |
| Unspecified | $28,827 | 27 | 6.1% |
| Education | $17,519 | 4 | 3.7% |
| Food and Beverage | $5,464 | 63 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,037 | 2 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $36.53 | 1 | 0.0% |
Payments by Type
General
$446,057
233 transactions
Research
$28,827
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $98,702 | 52 | $0 (2024) |
| GlaxoSmithKline, LLC. | $52,603 | 22 | $0 (2024) |
| PharmaEssentia USA Corporation | $48,221 | 7 | $0 (2024) |
| Celgene Corporation | $46,588 | 28 | $0 (2023) |
| Genentech, Inc. | $41,984 | 22 | $0 (2024) |
| Blueprint Medicines Corporation | $26,324 | 5 | $0 (2023) |
| ABBVIE INC. | $24,801 | 14 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $20,174 | 12 | $0 (2021) |
| F. Hoffmann-La Roche AG | $19,867 | 20 | $0 (2024) |
| Merck Sharp & Dohme LLC | $17,927 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $79,353 | 48 | Genentech, Inc. ($19,811) |
| 2023 | $106,575 | 30 | PharmaEssentia USA Corporation ($41,486) |
| 2022 | $87,916 | 37 | Blueprint Medicines Corporation ($21,476) |
| 2021 | $43,905 | 25 | Incyte Corporation ($12,969) |
| 2020 | $44,542 | 22 | Celgene Corporation ($18,086) |
| 2019 | $8,245 | 17 | Celgene Corporation ($2,953) |
| 2018 | $48,603 | 40 | Incyte Corporation ($15,800) |
| 2017 | $55,745 | 41 | Incyte Corporation ($28,641) |
All Payment Transactions
260 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $59.61 | General |
| 12/05/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $46.53 | General |
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,525.00 | General |
| 10/24/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $675.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) | ||||||
| 10/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $7,192.50 | General |
| 09/27/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $628.95 | General |
| 09/27/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $112.05 | General |
| 09/27/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $59.99 | General |
| 09/27/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $59.99 | General |
| 09/27/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $51.70 | General |
| 09/27/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 09/26/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $301.39 | General |
| 09/26/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $131.76 | General |
| 09/26/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $86.30 | General |
| 09/26/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $53.85 | General |
| 09/23/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,320.00 | General |
| 09/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 09/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $7,927.30 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $659.56 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $222.45 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $122.35 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | SOBI, INC | VONJO (Drug) | Consulting Fee | Cash or cash equivalent | $3,700.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/05/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $11,780.00 | General |
| 09/05/2024 | Genentech, Inc. | — | Travel and Lodging | In-kind items and services | $6,959.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: Stage 1 of a Phase II trial | F. Hoffmann-La Roche AG | $4,557 | 1 |
| Phase 2 Study Of PRM 151 In Subjects With Myelofibrosis | F. Hoffmann-La Roche AG | $3,252 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH RESEARCH AGREEMENT | Novartis Pharmaceuticals Corporation | $3,214 | 1 |
| To evaluate safety and efficacy of Idasanutlin in Polycythemia Vera patients | F. Hoffmann-La Roche AG | $2,268 | 4 |
| A Phase 3 study of monotherapy (MF) vs best supportive care (BSC) | Celgene Corporation | $2,250 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,153 | 4 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) | ABBVIE INC. | $2,050 | 3 |
| A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions | Celgene Corporation | $1,875 | 1 |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | ABBVIE INC. | $1,650 | 2 |
| A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) | ABBVIE INC. | $1,100 | 2 |
| ACE-536-MF-001 - A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence | Celgene Corporation | $1,082 | 1 |
| A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy & Safety Study of Fedratinib in Subjects w/ DIPSS-Intermediate or High-Risk PMF, post-PV MF, or post-ET MF & Previously Treated w/ Ruxolitinib incl. Sub-study w/ concomitant Luspatercept for anemia (FEDR-MF-001) | Celgene Corporation | $952.00 | 1 |
| A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001) | Celgene Corporation | $935.00 | 1 |
| Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsedx2FRefractory Myelofibrosis | ABBVIE INC. | $550.00 | 1 |
| A Phase 3 Study of [Treatment] in Patients with Mycosis Fungoides (CL-MF-13881) | Celgene Corporation | $476.00 | 1 |
| Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib | SANOFI-AVENTIS U.S. LLC | $463.39 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 25 | 30 | $6,756 | $2,891 |
| 2022 | 1 | 49 | 89 | $28,124 | $8,441 |
| 2021 | 3 | 78 | 126 | $42,947 | $13,282 |
| 2020 | 3 | 66 | 87 | $25,084 | $7,986 |
Total Patients
218
Total Services
332
Medicare Billing
$32,599
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $3,575 | $1,452 | 40.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 14 | 19 | $3,181 | $1,438 | 45.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 89 | $28,124 | $8,441 | 30.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 52 | 99 | $30,105 | $9,184 | 30.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 14 | 14 | $7,351 | $2,444 | 33.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 13 | $5,491 | $1,654 | 30.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 36 | 55 | $14,559 | $4,640 | 31.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 15 | 15 | $5,850 | $1,896 | 32.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 15 | 17 | $4,675 | $1,450 | 31.0% |
About Dr. Ruben Mesa, MD
Dr. Ruben Mesa, MD is a Hematology & Oncology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962480475.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruben Mesa, MD has received a total of $474,884 in payments from pharmaceutical and medical device companies, with $79,353 received in 2024. These payments were reported across 260 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($227,922).
As a Medicare-enrolled provider, Mesa has provided services to 218 Medicare beneficiaries, totaling 332 services with total Medicare billing of $32,599. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hematology
- Location Charlotte, NC
- Active Since 01/04/2006
- Last Updated 07/15/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1962480475
Products in Payments
- JAKAFI (Drug) $84,169
- BESREMI (Drug) $48,221
- INREBIC (Drug) $23,888
- Non-Covered Product (Drug) $9,528
- KEYTRUDA (Biological) $8,932
- DAURISMO (Drug) $7,725
- AGRYLIN (Biological) $4,270
- VONJO (Drug) $4,017
- OJJAARA (Drug) $3,200
- Jakavi (Drug) $2,948
- Luspatercept (Drug) $2,553
- AYVAKIT (Drug) $2,048
- Fedratinib (Drug) $1,904
- TECENTRIQ (Biological) $1,320
- Reblozyl (Drug) $935.00
- JAKAVI_JAKAFI_ONCOLOGY (Drug) $786.00
- JAK-2 (Drug) $463.39
- Vonjo (Drug) $243.62
- Inrebic (Drug) $113.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charlotte
Dr. Alan Zausner Skarbnik, Md, MD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Shebli Atrash, Md, MD
Hematology & Oncology — Payments: $718,073
Hematology & Oncology $718,073
Nasfat Shehadeh, Md, MD
Hematology & Oncology — Payments: $78,512
Hematology & Oncology $78,512
Justin Favaro, Md, MD
Hematology & Oncology — Payments: $35,791
Hematology & Oncology $35,791
Bei Hu, Md, MD
Hematology & Oncology — Payments: $16,154
Hematology & Oncology $16,154
Brittany Ragon, Md, MD
Hematology & Oncology — Payments: $13,167
Hematology & Oncology $13,167